Denna sida på svenska

Lukas Orre

Assistant professor

Visiting address : Kisp (Karolinska Institutet Science Park), Tomtebodavägen 23a, Alfa Floor 1, Mass Spectrometry 171 65 Solna, Sweden
Postal address : Department of Oncology-Pathology (OnkPat), K7, Research Group Lehtiö, Janne, Box 1031 171 21 Solna, Sweden
Delivery address : Kisp (Karolinska Institutet Science Park), Tomtebodavägen 23b, Alfa Floor 1 171 65 Solna, Sweden

Research description

Lung Cancer and Personalized Medicine

Lung cancer is by far the deadliest form of cancer and in many cases there are no available therapeutic options for patients with this disease. Targeted therapies that inhibit growth factor signaling in lung cancer raised hope for improved patient survival, but ten years after approval it is evident that monotherapy with these agents will only delay disease progression by a few months and in addition only in a small subset of patients.

It is becoming increasingly appreciated that the reasons for this lack of efficacy is that cancer is a heterogeneous disease. This is displayed in two ways. First, the molecular paths to lung cancer are not the same in different patients. This means that different patients will have different molecular drivers of their cancer and consequently they should be treated in different ways i.e. we should personalize the therapy. Second, the tumor cells that together build up a tumor in a patient are also heterogeneous i.e. each tumor is composed of several different clones of cells that can differ in mutation spectrum and cell type. These different cells within a single tumor will also respond differently to cancer therapy. A drug that efficiently kills one type of cells in the tumor can still leave other cancer cells unaffected. To efficiently kill all cancer cells within a tumor and ultimately cure the patient we need to combine several types of therapy.

In order to personalize cancer therapy and identify efficient therapy combinations we need biomarkers that can be used to predict if a specific type of therapy will be efficient in a specific patient. Once identified, the presence of these biomarkers can be measured in the tumor of a patient, and this information can then be used for rational selection of therapy.

The general aim of my research is to identify novel biomarkers and targets for cancer therapy to improve the treatment of lung cancer. To accomplish this I am developing and applying advanced methods as described below to study the effects of cancer therapy on cancer cells. By reading out the molecular response of cancer cells to different drugs in great detail we can identify the determinants of drug response or drug resistance, and use this information to suggest biomarkers and drug combinations for improved lung cancer therapy. 


Functional Proteomics and Systems Biology

The expression, and functions of proteins in a cell is what determines the phenotype, i.e. the characteristics of the cell. For example the expression and functional activity of proteins in a cell will determine if a cell is cancerous or not, and whether a cancer cell is sensitive for a specific type of treatment. Proteomics is the large-scale study of proteins in biological systems, or in other words methods that aim to comprehensively describe the protein landscape of a biological sample. The proteomics concept can be further developed into functional proteomics where the ambition is to also describe the functional state of proteins in large-scale experiments.

In depth mass spectrometry based proteomics

In our lab we use high-resolution orbitrap mass spectrometers to identify and quantify thousands of proteins in biological samples. More specifically, we have developed a method, HiRIEF-LC-MS (Nature Methods 2014) that allows us to study more than 10 000 unique proteins and their regulation in response to treatment in a single experiment. This analytical depth gives us the possibility to describe the molecular response of cancer cells to cancer therapy in great detail, which is essential to understand the effects of the treatment.


The activity of a protein is not only determined by the abundance of the protein. Since it is important for a cell to tightly regulate all cellular processes, the proteins are equipped with “molecular switches” that turn on or off certain functions of the proteins. This regulation is performed by adding or removing functional groups to the proteins in processes referred to as protein post-translational modification (PTM). The most well characterized type of PTM is protein phosphorylation and the phosphorylation pattern of proteins in cancer cells are commonly disturbed, which can result in for example increased cell proliferation or decreased apoptosis (cell death). Many targeted cancer therapies are aiming to restore the phosphorylation pattern in cancer cells to stop the uncontrolled cell growth and induce cell death. To fully understand the consequences of targeted therapies, it is therefor important to study changes in protein phosphorylation in response to treatment. In our lab we are setting up methods to specifically study protein phosphorylation, and these methods are then applied to analyze the effects of treatment on the phospho-proteome.

Protein subcellular localization and relocalization

The functions and activities of proteins are also determined by their specific localization in the cell. A protein can have one type of function when localized in the nucleus, and a completely different function when localized in the cytoplasm. More common maybe is that a protein is active when it is residing in one subcellular compartment and inactive when sequestered in another. Treatment of cells with different types of drugs will alter the subcellular localization of proteins, i.e. induce protein relocalization, which will alter the function of affected proteins. Currently, large-scale methods to study protein localization and relocalization are lacking. We are developing methods to comprehensively study the localization of proteins in cells, and these methods will be used to understand how proteins shuttle between different subcellular compartments in response to cancer therapy, and ultimately how this affects the drug sensitivity. 

Systems Biology

Systems biology is the combination of different levels of biological information in order to see the full picture. In practice this means that we merge the information generated by several different types of experiments used to study the same biological question. The data included in our systems biology analysis is generated by the proteomics methods described above, but we also include data describing the transcriptional activity of cancer cells in response to treatment (mRNA-level analysis) as well as the genomic background of the cells (DNA-level analysis). All this data is then used in concert to understand why the cancer cells from different tumors respond differently to cancer drugs. Ultimately this knowledge will help us tailor the best cancer therapy to each lung cancer patient with the ambition to cure him or her from the disease.


Secretome protein signature of human gastrointestinal stromal tumor cells
Berglund E, Daré E, Branca Rm, Akcakaya P, Fröbom R, Berggren Po, et al
Experimental cell research 2015;336(1):158-70

HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics
Branca Rm, Orre Lm, Johansson Hj, Granholm V, Huss M, Pérez-bercoff Å, et al
Nature methods 2014;11(1):59-62

SpliceVista, a tool for splice variant identification and visualization in shotgun proteomics data
Zhu Y, Hultin-rosenberg L, Forshed J, Branca Rm, Orre Lm, Lehtiö J
Molecular & cellular proteomics : MCP 2014;13(6):1552-62

S100A4 interacts with p53 in the nucleus and promotes p53 degradation
Orre Lm, Panizza E, Kaminskyy Vo, Vernet E, Gräslund T, Zhivotovsky B, et al
Oncogene 2013;32(49):5531-40

Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca2+-Binding Protein S100A6 in Papillary Thyroid Carcinoma
Sofiadis A, Dinets A, Orre Lm, Branca Rm, Juhlin Cc, Foukakis T, et al
THYROID 2010;20(10):1067-76

A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells
Stranneheim H, Orre Lm, Lehtio J, Flygare J

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer
De Petris L, Orre Lm, Kanter L, Pernemalm M, Koyi H, Lewensohn R, et al
LUNG CANCER 2009;63(3):410-7

Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery
Pernemalm M, Orre Lm, Lengqvist J, Wikstrom P, Lewensohn R, Lehtio J

Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms
Eriksson H, Lengqvist J, Hedlund J, Uhlen K, Orre Lm, Bjellqvist B, et al
PROTEOMICS 2008;8(15):3008-18

Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling
Orre Lm, Pernemalm M, Lengqvist J, Lewensohn R, Lehtio J

p53 is involved in clearance of ionizing radiation-induced RAD51 foci in a human colon cancer cell line
Orre Lm, Stenerlow B, Dhar S, Larsson R, Lewensohn R, Lehtio J

Rad51-related changes in global gene expression
Orre Lm, Falt S, Szeles A, Lewensohn R, Wennborg A, Flygare J

Show all publications